 Building BentrioTM brand and expanding in European markets 510k premarket notification for allergy indication submitted to the U.S. Food and Drug Administration FDA Distributors signed up for two key South East Asian countries, highlighting international expansion potential HAMILTON, BERMUDA ACCESSWIRE September 27, 2021 Altamira Therapeutics Ltd. NASDAQ:CYTO, a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today provided a business update on BentrioTM, its nasal spray for protection against airborne viruses and allergens. 